Jove
Visualize
Contact Us

Related Experiment Videos

Podophyllotoxin derivative VP 16-213.

A M Arnold

    Cancer Chemotherapy and Pharmacology
    |January 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    VP 16-213, a podophyllotoxin derivative, shows significant efficacy against small-cell lung cancer and other tumors. This drug causes the most lethal damage to cells in late S and G2 phases, with effectiveness dependent on administration schedule.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.

    European journal of cancer (Oxford, England : 1990)·2013
    Same author

    Replication of genetic loci for ages at menarche and menopause in the multi-ethnic Population Architecture using Genomics and Epidemiology (PAGE) study.

    Human reproduction (Oxford, England)·2013
    Same author

    Prediction and classification of cardiovascular disease risk in older adults with diabetes.

    Diabetologia·2012
    Same author

    Association of heat shock proteins with all-cause mortality.

    Age (Dordrecht, Netherlands)·2012
    Same author

    Concurrent change in dehydroepiandrosterone sulfate and functional performance in the oldest old: results from the Cardiovascular Health Study All Stars study.

    The journals of gerontology. Series A, Biological sciences and medical sciences·2010
    Same author

    Soluble intracellular adhesion molecule-1 is associated with cardiovascular disease risk and mortality in older adults.

    Journal of thrombosis and haemostasis : JTH·2006
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Area of Science:

    • Oncology
    • Pharmacology
    • Cell Biology

    Background:

    • VP 16-213 is a podophyllotoxin derivative undergoing phase-III clinical trials.
    • Its mechanism of action is not fully elucidated and differs from its parent compound.

    Purpose of the Study:

    • To investigate the efficacy and characteristics of VP 16-213 in cancer treatment.
    • To understand the cellular effects and optimal administration schedule for VP 16-213.

    Main Methods:

    • Evaluation of VP 16-213's impact on cancer cells, particularly in the L 1210 system.
    • Assessment of drug efficacy across different administration schedules (prolonged vs. bolus).

    Main Results:

    • VP 16-213 demonstrates significant activity against small-cell bronchial carcinoma as a single agent.

    Related Experiment Videos

  • Cellular damage is most pronounced in late S and G2 phases.
  • The drug exhibits schedule dependency, with prolonged administration potentially being more effective.
  • Potential utility in other lung tumors, testicular teratomas, and certain leukemias is suggested.
  • No long-term or cumulative toxicity has been reported; side effects are predictable.

    • Conclusions:

    • VP 16-213 is a promising chemotherapeutic agent, particularly for small-cell lung cancer.
    • Understanding its cell cycle effects and schedule dependency can optimize treatment strategies.
    • VP 16-213 presents a favorable toxicity profile with manageable side effects.